Cancer Moonshot℠ - Funding by Research Category
To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel of scientific experts as a working group to the National Cancer Advisory Board. In September of 2016, the Blue Ribbon Panel presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment, and care.
The following research categories align with these 10 recommendations:
| Research Category | Amount* |
|---|---|
| Network for Direct Patient Engagement | $16,733,788 |
| Cancer Immunotherapy Translational Science Network | $20,418,132 |
| Therapeutic Target Identification to Overcome Drug Resistance | $10,507,238 |
| A National Cancer Data Ecosystem for Sharing and Analysis | $850,000 |
| Fusion Oncoproteins in Childhood Cancers | $1,222,115 |
| Minimize Cancer Treatment’s Debilitating Side Effects | $6,699,835 |
| Prevention and Early Detection: Implementation of Evidence-Based Approaches | $24,170,151 |
| Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care | $0 |
| Generation of Human Tumor Atlases | $10,669,149 |
| Development of New Enabling Cancer Technologies | $16,121,154 |
| Other Cancer Moonshot Priority Activities (e.g., Partnership for Accelerating Cancer Therapies) | $17,014,767 |
| Total | $124,406,329 |
| * Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, and 2022 carryover accounts. | |